



KDIGO Controversies Conference on Novel Anemia Therapies in CKD

#KDIGOAnemiaTherapies

Pre-Recorded Plenary Presentations

Please watch in advance via the [conference website](#)

Discovery of the HIF Pathway
Sir Peter Ratcliffe

Pros and Cons of Non-Inferiority Studies
Wolfgang Winkelmayr

What Does a Regulator Need to See Before Approving a HIF Stabilizer? PMDA's
Perspective
Toshiyuki Takahashi, Mototsugu Tanaka, Mitsuhiro Ikuma, Wataru Asakura

Case Studies: Real-world experiences with the use of HIFs
Masaomi Nangaku

Thursday, December 9

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Introduction: Meeting Overview

(All times EST)

3:00 – 3:10 pm Welcome & Introductions
John Davis, KDIGO CEO & Wolfgang Winkelmayr, KDIGO Co-Chair

3:10 – 3:20 pm Conference Overview, Objectives, and Ground Rules
Elaine Ku & David Wheeler, Conference Co-Chairs

Plenary Session

3:20 – 3:45 pm HIF Stabilizer Trials in CKD/HD Patients – What Do the Data Really Show?
Jonathan Barratt

3:45 – 3:55 pm Q&A

3:55 – 4:20 pm Will We Need to Give Any Iron When We Prescribe HIF Stabilizers?
Jodie Babitt

4:20 – 4:30 pm Q&A

4:30 – 5:00 pm Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the
Management of Anemia in CKD
Iain Macdougall & Jay Wish

5:00 – 5:10 pm Q&A

5:10 – 5:30 pm Group Discussion

5:30 pm Preparations for Day 2 & Wrap Up
Elaine Ku & David Wheeler, Conference Co-Chairs



Friday, December 10

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Preliminary Breakout Group Reports & Discussion

(All times EST)

3:00 – 3:05 pm	Opening Remarks Elaine Ku & David Wheeler, Conference Co-Chairs
3:05 – 3:30 pm	Group 1: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients not on dialysis treatment Lucia Del Vecchio & Nav Tangri
3:30 – 3:40 pm	Q&A
3:40 – 4:05 pm	Group 2: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients treated with dialysis Kirsten Johansen & Masaomi Nangaku
4:05 – 4:15 pm	Q&A
4:15 – 4:25 pm	Break
4:25 – 4:50 pm	Group 3: Safety profile of HIF-PH inhibitors in CKD anemia management Sushrut Waikar & Andrzej Wiecek
4:50 – 5:00 pm	Q&A
5:00 – 5:25 pm	Group 4: Pathophysiology of HIFs and effects beyond hemoglobin Kai-Uwe Eckardt & Volker Haase
5:25 – 5:35 pm	Q&A
5:35 – 6:00 pm	Full Group Discussion

6:00 pm Preparations for Day 3 & Wrap Up
Elaine Ku & David Wheeler, Conference Co-Chairs

Saturday, December 11

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Breakout Session

(All times EST)

3:00 - 5:00 pm Group 1: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients not on dialysis treatment

4:00 - 6:00 pm Group 2: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients treated with dialysis

3:00 - 5:00 pm Group 3: Safety profile of HIF-PH inhibitors in CKD anemia management

3:00 - 5:00 pm Group 4: Pathophysiology of HIFs and effects beyond hemoglobin

Sunday, December 12

12:00pm PST / 3:00pm EST / 8:00pm GMT / 9:00pm CET
(5:00am JST / 7:00am AEDT +1 day)

Final Breakout Group Reports & Discussion

(All times EST)

3:00 – 3:05 pm Opening Remarks
Elaine Ku & David Wheeler, Conference Co-Chairs

3:05 – 3:30 pm	Group 4: Pathophysiology of HIFs and effects beyond hemoglobin Kai-Uwe Eckardt & Volker Haase
3:30 – 3:40 pm	Q&A
3:40 – 4:05 pm	Group 3: Safety profile of HIF-PH inhibitors in CKD anemia management Sushrut Waikar & Andrzej Wiecek
4:05 – 4:15 pm	Q&A
4:15 – 4:25 pm	Break
4:25 – 4:50 pm	Group 2: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients treated with dialysis Kirsten Johansen & Masaomi Nangaku
4:50 – 5:00 pm	Q&A
5:00 – 5:25 pm	Group 1: Therapeutic use of HIF-PH inhibitors vs. current therapies in anemia management: CKD patients not on dialysis treatment Lucia Del Vecchio & Nav Tangri
5:25 – 5:35 pm	Q&A
5:35 – 6:00 pm	Full Group Discussion
6:00 pm	Closing Remarks & Next Steps Elaine Ku & David Wheeler, Conference Co-Chairs